JCR Pharmaceuticals Co., Ltd. Stocks

¥ 622Last Updated 12.03.2026

Issuer Rating

4/7

Performance

Average

Risk

Moderate

Recommendation

Hold

Market Cap

¥ 496.41M

Buy
Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
¥ 622
Key Takeaways

Risk factor

Considerable default risk

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very weak growth

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

JCR Pharmaceuticals Co., Ltd., a specialty pharmaceuticals company, engages in the research, development, manufacture, import and export, and sale of pharmaceutical products, regenerative medicines, and drug substances in Japan. It offers various therapeutic products, including GROWJECT used for the treatment of growth hormone deficiency and short stature; IZCARGO to treat Mucopolysaccharidosis type II; Agalsidase Beta...

Company Valuation

Slightly overvalued
3/7

Based on key historical and expected multiples, the stock is slightly overvalued relative to its peers. In particular, the stock is overpriced on P/E, of fair value on EV

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Somewhat favourable
5/7

The average target price of 4552.T is 887 and suggests 43% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incre

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis
X-channel

Buy

Sell

0 more stocks